Thema: Presse: Vaccination feasible in malignant glioma
Presse: Vaccination feasible in malignant glioma
Anne[a]
04.06.2004 11:37:30
Vaccination Feasible in Malignant Glioma
Laurie Barclay, MD
Vaccination with tumor-lysate-pulsed dendritic cells appears to be a feasible, safe, and bioactive potential treatment for glioblastoma multiforme (GBM), according to a presentation on May 3 at the 72nd annual meeting of the American Association of Neurological Surgeons in Orlando, Florida. This report is also in press in Cancer Research.
"We are very encouraged by the results, with median survival of 133 weeks for the study patients compared with 30 weeks for the control patients," presenter and lead author John S. Yu, MD, a neurosurgeon at Cedars-Sinai Health Systems in Los Angeles, California, told Medscape. "This therapy appears to be safe and to have potent biological activity."
At present, average survival for GBM is between 52 and 76 weeks, with 90% to 95% of patients surviving less than two years. Currently available treatment options of surgical resection followed by radiotherapy and chemotherapy have not significantly altered life expectancy.
Earlier research has suggested that vaccination with autologous tumor peptide-pulsed dendritic cells can enhance tumor-reactive cell activity and tumor infiltration.
In this phase I trial designed to study the safety and bioactivity of tumor lysate-pulsed dendritic cell vaccination for the treatment of GBM, tumor lysate from the surgically resected GBM was used as an antigen source. Fourteen patients were vaccinated three times at intervals of two weeks with autologous dendritic cells combined with tumor lysate.
Of 10 patients tested for the development of cytotoxicity, six had robust systemic cytotoxicity based on interferon-alpha release in response to tumor lysate after vaccination. Four of these patients also had a significant expansion in CD8+ antigen-specific T-cell clones.
Of six patients who underwent repeat resection for recurrent tumor, three patients had a significant CD8+ T-cell infiltrate within the tumor.
Median survival for eight patients with recurrent glioblastoma who received vaccination was 133 weeks compared with 30 weeks for 26 patients with recurrent glioblastoma who did not receive vaccination (P = .0013).
"We are confirming the effect this therapy has on survival through a phase II study and are working on developing a multi-institutional phase III trial," Dr. Yu said.
A National Institutes of Health grant to Dr. Yu supported this study. The authors have no financial disclosures.
AANS 72nd Annual Meeting: Abstract 709. Presented May 3, 2004.
Reviewed by Gary D. Vogin, MD
Laurie Barclay, MD Freelance writer for Medscape Medical News. © 2004 Medscape
May 5, 2004
Laurie Barclay, MD
Vaccination with tumor-lysate-pulsed dendritic cells appears to be a feasible, safe, and bioactive potential treatment for glioblastoma multiforme (GBM), according to a presentation on May 3 at the 72nd annual meeting of the American Association of Neurological Surgeons in Orlando, Florida. This report is also in press in Cancer Research.
"We are very encouraged by the results, with median survival of 133 weeks for the study patients compared with 30 weeks for the control patients," presenter and lead author John S. Yu, MD, a neurosurgeon at Cedars-Sinai Health Systems in Los Angeles, California, told Medscape. "This therapy appears to be safe and to have potent biological activity."
At present, average survival for GBM is between 52 and 76 weeks, with 90% to 95% of patients surviving less than two years. Currently available treatment options of surgical resection followed by radiotherapy and chemotherapy have not significantly altered life expectancy.
Earlier research has suggested that vaccination with autologous tumor peptide-pulsed dendritic cells can enhance tumor-reactive cell activity and tumor infiltration.
In this phase I trial designed to study the safety and bioactivity of tumor lysate-pulsed dendritic cell vaccination for the treatment of GBM, tumor lysate from the surgically resected GBM was used as an antigen source. Fourteen patients were vaccinated three times at intervals of two weeks with autologous dendritic cells combined with tumor lysate.
Of 10 patients tested for the development of cytotoxicity, six had robust systemic cytotoxicity based on interferon-alpha release in response to tumor lysate after vaccination. Four of these patients also had a significant expansion in CD8+ antigen-specific T-cell clones.
Of six patients who underwent repeat resection for recurrent tumor, three patients had a significant CD8+ T-cell infiltrate within the tumor.
Median survival for eight patients with recurrent glioblastoma who received vaccination was 133 weeks compared with 30 weeks for 26 patients with recurrent glioblastoma who did not receive vaccination (P = .0013).
"We are confirming the effect this therapy has on survival through a phase II study and are working on developing a multi-institutional phase III trial," Dr. Yu said.
A National Institutes of Health grant to Dr. Yu supported this study. The authors have no financial disclosures.
AANS 72nd Annual Meeting: Abstract 709. Presented May 3, 2004.
Reviewed by Gary D. Vogin, MD
Laurie Barclay, MD Freelance writer for Medscape Medical News. © 2004 Medscape
May 5, 2004
Anne[a]
Karin[a]
04.06.2004 12:50:00
Wenn ich´s richtig verstanden habe, heißt das: mit Tumor-Eiweiß geladene dendritische Zellen können höhere Infiltrations- und Wachstumsraten zur Folge haben, was aber bei Ladung mit Tumor-Lysate nicht der Fall sei? Lysate??? (nur für den Laien!).
Außerdem stellt sich die Frage, ob man es riskieren kann seine Behandlung (bei schnell wachsendem GBM), für längeren Zeitraum (Monate) nur mit dendritischen Zellen durchzuführen, oder ob diese Behandlung sich in ein zytotoxisches Konzept einfügen läßt. Falls letzteres der Fall ist: wann? Vor Chemo würden dann günstigenfalls Zellen des Immunsystems aktiviert (durch die Impfung), die dann durch die Chemo im Rundumschlag mit Krebszellen wieder vernichtet würden, oder wie? Welche Alternative, denn nach der Chemo ist ja auch immer vor der Chemo???
Außerdem stellt sich die Frage, ob man es riskieren kann seine Behandlung (bei schnell wachsendem GBM), für längeren Zeitraum (Monate) nur mit dendritischen Zellen durchzuführen, oder ob diese Behandlung sich in ein zytotoxisches Konzept einfügen läßt. Falls letzteres der Fall ist: wann? Vor Chemo würden dann günstigenfalls Zellen des Immunsystems aktiviert (durch die Impfung), die dann durch die Chemo im Rundumschlag mit Krebszellen wieder vernichtet würden, oder wie? Welche Alternative, denn nach der Chemo ist ja auch immer vor der Chemo???
Karin[a]